Epidemiology of hepatitis C virus infection in Australia (Q35071449)

6 August 2017

1 reference

title

Epidemiology of hepatitis C virus infection in Australia. (English)

1 reference

6 August 2017

0 references

1 reference

1 reference

1 reference

Matthew Law

1 reference

6 August 2017

John M Kaldor

1 reference

6 August 2017

Gregory J Dore

1 reference

6 August 2017

Margaret MacDonald

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Journal of Clinical Virology

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

171-184

1 reference

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Hepatitis C virus infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Hepatitis C genotypes in Australian haemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Hepatitis C virus genotypes in a cohort of Australian blood donors and haemophiliac and liver transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Post-transfusion hepatitis in Australia. Report of the Australian Red Cross study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Spread of bloodborne viruses among Australian prison entrants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Epidemiology of hepatitis C virus infection among injecting drug users in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Prevalence of hepatitis C virus infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Is severe liver disease a common outcome for people with chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Epidemiology and hepatitis C virus in Victoria.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Prevalence of hepatitis C infection in pregnant women in South Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Predictive markers for hepatitis C antibody ELISA specificity in Australian blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Molecular epidemiology of hepatitis C in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Hepatitis C infection in children: a Melbourne perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Which patients with hepatitis C develop liver complications?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Hepatitis C virus genotypes in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Transmission of hepatitis C virus: rates, routes, and cofactors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Risk behaviours of young Indo-Chinese injecting drug users in Sydney and Melbourne

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Prevalence of hepatitis C virus and genotype distribution in an Australian volunteer blood donor population

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Hepatitis C virus infection in Victorian injecting drug users in 1971

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Changes in hepatitis C-related liver disease in a large clinic population

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Sexual transmission of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Investigation of notifications of hepatitis C in 1994: the experience of three health departments.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

Epidemiology of hepatitis C: geographic differences and temporal trends

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900116-6

7 January 2021

10.1016/S1386-6532(02)00116-6

Identifiers

DOI

1 reference

6 August 2017

1 reference